Search results
Guillain-Barre syndrome ‘more common than expected’ with RSV vaccine in older people, CDC reiterates
The Columbian· 7 days agoReports of a rare nervous system disorder were “more common than expected” in older U.S. adults who...
After key rare disease win, Annexon eyes $144 million raise - San Francisco Business Times
The Business Journals· 1 day agoThe Brisbane company (Nasdaq: ANNX) said Tuesday that its drug, called ANX-005, produced positive...
Guillain-Barre Syndrome Rates After RSV Shots in Sync With Trial Data, CDC Says
MedPage Today· 7 days agoReports of Guillain-Barré syndrome (GBS) following respiratory syncytial virus (RSV) vaccination in adults ages 60 and up were higher than expected, but ...
Annexon shares leap as Guillain-Barré drug reduces disability in phase 3
FierceBiotech· 2 days agoAnnexon’s monoclonal antibody ANX005 reduced disability in patients with the rare autoimmune...
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Zacks via Yahoo Finance· 1 day agoAnnexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of...
Adults 60+ Will Have 3 RSV Vaccines to Choose From This Year
Verywell Health via Yahoo News· 20 hours agoImportantly, none of the participants experienced Guillain-Barré syndrome (GBS), a rare neurological...
Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study
Benzinga via Yahoo Finance· 2 days agoOn Tuesday, Annexon Inc (NASDAQ:ANNX) released topline results from its Phase 3 trial in patients...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 6 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Annexon’s ANX005 offers improvement in Phase III GBS trial
Clinical Trials Arena via Yahoo Finance· 1 day agoAnnexon Biosciences has reported positive topline results from its Phase III clinical trial of...
Annexon surges 48% after scheduling update for Guillain-Barré Syndrome drug data
Market Watch· 3 days agoThe company said Monday it will discuss results for its ANX005 treatment for Guillain-Barré Syndrome, with a conference call and webcast slated for Tuesday ...